{
    "clinical_study": {
        "@rank": "102662", 
        "acronym": "CAP7-1", 
        "arm_group": [
            {
                "arm_group_label": "Small cell lung cancer", 
                "arm_group_type": "Experimental", 
                "description": "Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment"
            }, 
            {
                "arm_group_label": "Non small cell lung cancer", 
                "arm_group_type": "Experimental", 
                "description": "Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy"
            }, 
            {
                "arm_group_label": "biliary tract cancer", 
                "arm_group_type": "Experimental", 
                "description": "Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate\n      and rate of disease stabilization, as defined by the below primary and secondary endpoints,\n      in patients with NSCLC, SCLC or biliary cancer who have progressed despite one or more\n      previous chemotherapy line."
        }, 
        "brief_title": "CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Endstage Solid Carcinomas in Adults", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "A phase II evaluation will be performed in adult patients in parallel studies in 3 tumor\n      types: NSCLC, SCLC and Biliary Tract Cancer.  All patients will have advanced or metastatic\n      disease with primary or secondary resistance to standard therapy.  In each tumor type the\n      patients will be randomized to receive either therapy with CAP7.1 or best supportive care\n      according to institution standards. Patient in the Control group who progress may cross over\n      to CAP7.1, however these patients will be analyzed separately from the patients randomized\n      to CAP7.1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically- or cytologically-confirmed, advanced disease with documented\n             progression (RECIST1.1.) after one or several chemotherapy line\n\n          -  Patients may also have received molecular targeted therapy and progressed while on\n             therapy or after completion\n\n          -  Must have recovered from the acute reversible effects of previous anti-cancer\n             chemotherapy, usually 3-4 weeks after myelosuppressive chemotherapy\n\n        Exclusion Criteria:\n\n          -  Serious concurrent medical condition, which could affect compliance with the protocol\n             or interpretation of results.\n\n          -  Patients with uncontrolled infection and patients known to be infected with the human\n             immunodeficiency virus (HIV) or  hepatitis  infection are not eligible for the study\n\n          -  Pregnancy or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094560", 
            "org_study_id": "CPN710102", 
            "secondary_id": "2012-002378-30"
        }, 
        "intervention": {
            "arm_group_label": [
                "Small cell lung cancer", 
                "Non small cell lung cancer", 
                "biliary tract cancer"
            ], 
            "description": "CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase", 
            "intervention_name": "CAP7.1", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "therapy refractory", 
            "endstage", 
            "solid tumours"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "Ulrich-Ulrich-Frank.Pape@charite.de", 
                "last_name": "Ulrich F Pape, MD.", 
                "phone": "+49-(0)30-450 665 209"
            }, 
            "contact_backup": {
                "email": "a.steingraeber@charite.de", 
                "last_name": "Andrea Steingr\u00e4ber", 
                "phone": "+49-(0)30-450 665 209"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Charite, University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)", 
        "overall_contact": {
            "email": "n.utku@cellact.eu", 
            "last_name": "Nal\u00e2n Utku, M.D. Ph.D.", 
            "phone": "+4923197426350"
        }, 
        "overall_contact_backup": {
            "email": "barbara.schroeder@cellact.eu", 
            "last_name": "Barbara Schr\u00f6der", 
            "phone": "+4923197426350"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of antitumor activity  based on RECIST 1.1 criteria (complete response; partial response; stable disease)", 
            "measure": "Time to disease progression", 
            "safety_issue": "No", 
            "time_frame": "18 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment of overall survival (OS)", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "CellAct Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CellAct Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}